The activated p38γ/c-Jun/MMP9 complex observed in human colon cancer tissues links these laboratory findings with clinical observations, illustrating that p38γ acts as both an activator and a cofactor of a transcription factor, which diversifies potential therapeutic approaches in CRC. This evidence concerns the gene MMP9 and colonic neoplasm.